Key result
Patients with atrial fibrillation treated with vitamin K antagonists demonstrated significantly better knowledge scores compared to those on non-VKA oral anticoagulants (58% vs 54.3%, p=0.0002), alongside significant regional differences across centers.
Why the study?
Regional differences among Polish patients regarding their awareness of AF diagnosis and oral anticoagulation use had not been evaluated.
Cross-Sectional (n=1,525)
Yes
Answers are grounded in this paper and cite their sources.
Patients with atrial fibrillation demonstrate significant regional differences in disease knowledge and oral anticoagulant prescription patterns, highlighting the need for targeted educational initiatives.
BACKGROUND The Jessa Atrial Fibrillation Knowledge Questionnaire (JAKQ) was successfully used to assess knowledge gaps in patients with atrial fibrillation (AF). AIMS To evaluate the regional differences among Polish patients in their awareness of AF diagnosis and oral anticoagulation use. METHODS A total of 1583 patients with AF at a median (IQR) age of 72 (66-79) years completed the JAKQ in 3 cardiology centers (center I, Kraków; center II, Toruń; center III, Kielce) from January 2017 to June 2018. The final analysis included 1525 patients, 32.9% were on vitamin K antagonists (VKAs) and 67.1% on non-VKA oral anticoagulants (NOACs), that is, rivaroxaban and dabigatran (28.9% each), and apixaban (9.3%). RESULTS The mean (SD) score on the JAKQ was 55.5% (18.4%) with better results among patients on VKAs compared with NOACs (58% [18.3%] vs 54.3% [18.4%]; P = 0.0002) with time from AF diagnosis more than 12 months (57.4% [17.5%] vs 50% [19.9%]; P <0.0001). There was a significant difference in the knowledge scores between the 3 centers (I, 59.5%; II, 48.5%; III, 54.3%; P <0.0001). In all centers the number of correct answers correlated inversely with patient's age (r = -0.20; P <0.0001). NOACs were more frequently used in center III. The percentage of correct responses was lower in patients on reduced NOAC doses (35.4% of patients on NOACs), compared with the full-dose NOAC groups in center I (56.9% vs 62.5%; P = 0.012) and II (48.1% vs 56.2%; P = 0.003). CONCLUSIONS Patients from a high-volume academic center showed better knowledge than their peers from district hospitals. There are large regional differences in prescription patterns of oral anticoagulants, including the preferred NOAC.
No takes yet. Share an insight, caveat, or question.
Janion−Sadowska et al. (2019) conducted a cross-sectional in Atrial fibrillation (n=1,525). Vitamin K antagonists (VKAs) vs. Non-VKA oral anticoagulants (NOACs) was evaluated on Mean score on the Jessa Atrial Fibrillation Knowledge Questionnaire (JAKQ) (p=0.0002). Patients with atrial fibrillation treated with vitamin K antagonists demonstrated significantly better knowledge scores compared to those on non-VKA oral anticoagulants (58% vs 54.3%, p=0.0002), alongside significant regional differences across centers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: